tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ALNY Stock Latest News

Alnylam and Regeneron Join Forces in Promising Alzheimer’s Study
Company AnnouncementsAlnylam and Regeneron Join Forces in Promising Alzheimer’s Study
1d ago
ALNY
REGN
Alnylam price target raised to $475 from $405 at Morgan Stanley
PremiumThe Fly
Alnylam price target raised to $475 from $405 at Morgan Stanley
4d ago
ALNY
Alnylam price target raised to $495 from $441 at Stifel
PremiumThe Fly
Alnylam price target raised to $495 from $441 at Stifel
4d ago
ALNY
Alnylam Pharma Secures $500M Credit Agreement
PremiumCompany Announcements
Alnylam Pharma Secures $500M Credit Agreement
7d ago
8K
ALNY
Alnylam doses first patient in ZENITH trial
PremiumThe Fly
Alnylam doses first patient in ZENITH trial
9d ago
ALNY
Alnylam announces results from HELIOS-B Phase 3 study of AMVUTTRA
PremiumThe FlyAlnylam announces results from HELIOS-B Phase 3 study of AMVUTTRA
12d ago
ALNY
Alnylam Pharmaceuticals Completes Phase 1 Study of ALN-AGT01 RVR
Premium
Company Announcements
Alnylam Pharmaceuticals Completes Phase 1 Study of ALN-AGT01 RVR
21d ago
ALNY
Alnylam price target raised to $500 from $435 at RBC Capital
Premium
The Fly
Alnylam price target raised to $500 from $435 at RBC Capital
21d ago
ALNY
Alnylam price target raised to $520 from $453 at BofA
PremiumThe Fly
Alnylam price target raised to $520 from $453 at BofA
23d ago
ALNY
Alnylam Pharma: Promising Growth Driven by ATTR-CM Franchise and siRNA Platform Expansion
PremiumRatings
Alnylam Pharma: Promising Growth Driven by ATTR-CM Franchise and siRNA Platform Expansion
23d ago
ALNY
Alnylam Pharma Executes Note Repurchase Transactions
PremiumCompany Announcements
Alnylam Pharma Executes Note Repurchase Transactions
28d ago
8K
ALNY
Alnylam Pharma Announces $500M Convertible Notes Offering
PremiumCompany Announcements
Alnylam Pharma Announces $500M Convertible Notes Offering
1M ago
8K
ALNY
Alnylam announces $500M convertible senior notes offering
PremiumThe FlyAlnylam announces $500M convertible senior notes offering
1M ago
ALNY
Alnylam price target raised to $470 from $450 at BMO Capital
Premium
The Fly
Alnylam price target raised to $470 from $450 at BMO Capital
1M ago
ALNY
CHRO
Alnylam’s TRITON-CM Study: A Potential Breakthrough in Cardiomyopathy Treatment
Premium
Company Announcements
Alnylam’s TRITON-CM Study: A Potential Breakthrough in Cardiomyopathy Treatment
1M ago
ALNY
Alnylam’s Vutrisiran Study Advances in Treating Rare Cardiomyopathy
PremiumCompany Announcements
Alnylam’s Vutrisiran Study Advances in Treating Rare Cardiomyopathy
1M ago
ALNY
Cautious Hold Rating for Alnylam Pharma Amid Uncertain Efficacy of Zilebesiran in KARDIA-3 Trial
PremiumRatings
Cautious Hold Rating for Alnylam Pharma Amid Uncertain Efficacy of Zilebesiran in KARDIA-3 Trial
1M ago
ALNY
Alnylam price target raised to $583 from $527 at Citi
PremiumThe Fly
Alnylam price target raised to $583 from $527 at Citi
1M ago
ALNY
Positive Outlook on Alnylam Pharma’s Hypertension and ATTR-CM Developments
PremiumRatings
Positive Outlook on Alnylam Pharma’s Hypertension and ATTR-CM Developments
1M ago
ALNY
Cautious Hold Rating on Alnylam Pharma Amid Promising Yet Inconclusive Zilebesiran Trial Results
PremiumRatingsCautious Hold Rating on Alnylam Pharma Amid Promising Yet Inconclusive Zilebesiran Trial Results
1M ago
ALNY
Buy Rating for Alnylam Pharma Driven by Promising Zilebesiran Developments and Strategic Partnership with Roche
Premium
Ratings
Buy Rating for Alnylam Pharma Driven by Promising Zilebesiran Developments and Strategic Partnership with Roche
1M ago
ALNY
Positive Outlook on Alnylam Pharma: Buy Rating Backed by Zilebesiran’s Potential and Amvuttra’s Market Opportunity
Premium
Ratings
Positive Outlook on Alnylam Pharma: Buy Rating Backed by Zilebesiran’s Potential and Amvuttra’s Market Opportunity
1M ago
ALNY

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >